Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBITDA (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed EBITDA for 13 consecutive years, with $247.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 385.71% to $247.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$82.5 million, a 79.12% increase, with the full-year FY2025 number at -$82.5 million, up 79.12% from a year prior.
  • EBITDA was $247.4 million for Q4 2025 at Iovance Biotherapeutics, up from -$94.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $247.4 million in Q4 2025 to a low of -$122.7 million in Q3 2023.
  • A 3-year average of -$78.6 million and a median of -$110.5 million in 2023 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 385.71% in 2025; the steepest drop was 11.64% in 2025.
  • Iovance Biotherapeutics' EBITDA stood at -$121.3 million in 2023, then grew by 28.6% to -$86.6 million in 2024, then soared by 385.71% to $247.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's EBITDA are $247.4 million (Q4 2025), -$94.9 million (Q3 2025), and -$113.8 million (Q2 2025).